Ensayos Clínicos

Ovario 1ª Línea

Reclutamiento

ENGOT-ov62/GEICO 129-O/N-Plus

PI: Purificación Estevez CoPI: Arantzazu Barquin

A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy

Ovario 1ª Línea

Reclutamiento

ENGOT-OV63/GEICO 110-0/NIRVANA

PI: Antonio González

A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib versus Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Following a Front-Line Complete Cytoreduction Surgery

Ovario 1ª Línea

Reclutamiento

ENGOT-ov84/GEICO 141-O/MK-2870-022/TROFUSE-022-EvoPAR Ovarian01

PI: Antonio González

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.MK-2870/022-PARPi (EvoPAR Ovarian01)

Ovario 1ª Línea

Reclutamiento

ENGOT-OV85/GEICO 151-O/MK-2870-021 /TROFUSE-021

PI: Alejandro Pérez-Fidalgo

“Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy.GINECO/MK-2870-021

Ovario 1ª Línea

Reclutamiento

ENGOT-OV89/GEICO 144-O/DESTINY-OVARIAN 01

PI: Antonio González CoPI: Luis Manso

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer.DESTINY-OVARIAN 01

Ovario 1ª Línea

Start Up

ENGOT-ov105/GEICO 195-O/BEHOLD-Ovarian03

PI: Raúl Márquez

Ovario 1ª Línea

Start Up

ENGOT-OV57/GEICO 109-O/AGO-OVAR 28

PI: Lydia Gaba

Ovario 1ª Línea

Start Up

ENGOT-ov106/MAESTRA3

PI: Antonio González

Ovario 1ª Línea

Start Up

ENGOT-ov107/REJOICE Ovarian05/MK5909-008

PI: Lydia Gaba

Ovario 1ª Línea

Seguimiento

ENGOT-ov45/GEICO 74-O/ATHENA

PI: Ana Oaknin

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovario 1ª Línea

Seguimiento

ENGOT-ov43/GEICO 80-O/7339-001

PI: Antonio González

Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)

Ovario Recaída

Reclutamiento

ENGOT ov77/GEICO 136-O/REJOICE-ovarian 01

PI: Lydia Gaba

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Ovario Recaída

Reclutamiento

ENGOT-ov81/GEICO 154-O/RAMP 301

PI: Ana Oaknin

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Ovario Recaída

Reclutamiento

ENGOT-ov84/GEICO 141-O/MK-2870-022

PI: Antonio González

Ovario Recaída

Reclutamiento

ENGOT-ov83/GEICO 146-O/CATALINA-2/TORL

PI: Ana Oaknin

“A Phase 2 study evaluating the efficacy and safety of TORL-1-23 in Women with advanced platinum-resistant epithelial ovarian cancer (including primary peritoneal and fallopian tube cancers) expressing Claudin 6 (CLdn6)” NOGGO/TORL

Ovario Recaída

Start Up

APGOT-ov14/GEICO 169-O/TROY

PI: A. Cortés CoPI: A. Madariaga

Ovario Recaída

Start Up

ENGOT-ov101/GEICO 176-O/NAPISTAR 3-01

PI: Antonio González CoPI: Pau Guillén

Ovario Recaída

Start Up

ENGOT-ov102/GEICO 181-O/REJOICE-Ovarian 04

PI: Luis Manso

Ovario Recaída

Start Up

ENGOTov103/GEICO 177-O/RAINFOL-07

PI: Ana Oaknin CoPI: Pablo Andreu Cobo

Ovario Recaída

Start Up

ENGOT-ov104/GEICO 192-O/REJOICE-Ovarian 03

PI: Ana Oaknin

Ovario Recaída

Start Up

ENGOT-ov93/GEICO 170-O/TREVI

PI: Lydia Gaba

Ovario Recaída

Start Up

ENGOT-ov94/GEICO 171-O/INCB123667-203

PI: Ignacio Romero

Ovario Recaída

Start Up

ENGOT-ov95/GEICO 172-O/INCB 123667-305

PI: Ignacio Romero

Ovario Recaída

Start Up

ENGOT-ov96/GEICO 173-O/GCT1184-04 (RAINFOL-04)

PI: Ignacio Romero

Ovario Recaída

Start Up

ENGOT-ov97/GEICO 174-O/FRAmework-01

PI: Fernando Gálvez

Ovario Recaída

Start Up

ENGOT-ov98/GEICO 175-O/BEHOLD-OVARIAN 01

PI: Yolanda García

Ovario Recaída

Start Up

ENGOT-ov99/GEICO 180-O/BEHOLD-OVARIAN 02

PI: Andrés Redondo

Ovario Recaída

Start Up

ENGOT-ov109/ASPENOVA

PI: Alejandro Martínez

Ovario Recaída

Seguimiento

ENGOT-ov76/GEICO 127-O/GLORIOSA

PI: Antonio González CoPI: Mª Jesús Bermejo

Randomized Phase 3 Trial for Mirvetuximab + Bevatuximab manteinance in FR@High PSOC Patients

Ovario Recaída

Seguimiento

ENGOT gyn5/GEICO 131-O/NXP 800

PI: Ana Oaknin

A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

Ovario Recaída

Seguimiento

GEICO 114-O/ART0380C001

PI: Antonio González CoPI: María Quindós

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Ovario Recaída

Seguimiento

ENGOT ov72/GEICO 122-O/ROSELLA

PI: Ana Oaknin

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Ovario Recaída

Seguimiento

ENGOT-ov61/GEICO 96-O/EPIK-O

PI: Antonio González

Phase III, multi-center, randomized (1:1), open label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy (wPac or PLD), in participants with no germline BRCA mutation detected, platinum-resistant or refractory, HGSOC

Ovario Recaída

Seguimiento

ENGOT-ov55/GEICO 91-O/MIRASOL

PI: Yolanda García CoPI: Paula Guillén

A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Ovario Recaída

Seguimiento

ENGOT-ov67/GEICO 106-O/UPLIFT

PI: Alejandro Pérez Fidalgo

A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Ovario Recaída

Seguimiento

ENGOT-ov50/GEICO 82-O/INNOVATE 3

PI: Antonio González

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of patients with recurrent ovarian cancer not suitable for platinum treatment (ROC-NP)

Ovario Recaída

Seguimiento

ENGOT-ov68/GEICO 112-O/ARTISTRY-7

PI: Andrés Redondo

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)”

Ovario Recaída

Seguimiento

ENGOT-OV86/GEICO 152-O/RAINFOL-OV2

PI: María Quindós

“A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer”RAINFOL-OV2

Cérvix Localmente Avanzado

Seguimiento

GEICO 78-C/ATOMICC

PI: Roberta Mazzeo

A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation

Cérvix Localmente Avanzado

Seguimiento

ENGOT-cx12/GEICO 84-C/GCT1015-07

PI: Antonio González CoPI: Jerónimo Martínez García

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Metastatic or Recurrent Cervical Cancer”

Cérvix Localmente Avanzado

Seguimiento

ENGOT-cx11/GEICO 86-C/MK3475-A18

PI: Ana Oaknin

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer”

Cérvix Localmente Avanzado

Seguimiento

ENGOT-cx8/GEICO 113-C/TV205

PI: Ana Oaknin

Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante

Cérvix Metastásico

Reclutamiento

ENGOT-cx19/GEICO 133-C/eVolve-Cervical

PI: Ana Oaknin

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

Cérvix Metastásico

Start Up

ENGOT-cx22/GEICO 185-C/TroFuse-036

PI: Lorena Fariñas

Cérvix Metastásico

Seguimiento

ENGOT cx20/GEICO 138-C/MK2870-020

PI: Ana Oaknin CoPI: Luis Manso

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer

Endometrio Localizado

Reclutamiento

GEICO 137-E/NADIA

PI: Alejandro Pérez-Fidalgo CoPI: Lydia Gaba

PHASE II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial cancer.NADIA

Endometrio Localizado

Seguimiento

ENGOT-EN2/GEICO 47-E

PI: Ana Santaballa

A Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. A Phase II, multicenter, prospective, open-label, randomized, controlled study.

Endometrio Avanzado

Reclutamiento

ENGOT-EN28/GEICO 160-E/Bluestar-Endometrial01

PI: Marta Gil

A phase III, Randomized, Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus treatment of Physician´s choice in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer who progress after Platinum-based Chemotherapy and Anti PD-1/anti-PD-L1 therapy

Endometrio Avanzado

Reclutamiento

ENGOT-EN25/GEICO 153-E/BNT 323-01

PI: Jesús Rubio CoPI: Cristina Churruca

“A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer.”

Endometrio Avanzado

Reclutamiento

ENGOT-EN24/GEICO 147-E/DESTINY

PI: Ignacio Romero

An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer”(DESTINY)

Endometrio Avanzado

Reclutamiento

ENGOT-EN30/GEICO 161-E/DESTINY Endometrial 02

PI: María Quindós

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan versus Standard of Care (Carboplatin in Combination with Paclitaxel) as Adjuvant Treatment for HER2-expressing (IHC 3+/IHC 2+) Endometrial Cancer

Endometrio Avanzado

Reclutamiento

ENGOT-en31/GEICO 158-E/RAINFOL 03

PI: António González

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Endometrio Avanzado

Reclutamiento

ENGOT-en8/GEICO 160-E/ROCSAN

PI: Eva Guerra

An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

Endometrio Avanzado

Reclutamiento

ENGOT-EN29/GEICO 159-E/TroFuse-033

PI: Luis Manso

“A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer

Endometrio Avanzado

Start Up

ENGOT-en34/GEICO 167-E/BEHOLD ENDOMETRIAL 01/GSK- 224038

PI: Ana Oaknin

Endometrio Avanzado

Start Up

ENGOT-en33/GEICO 188-E/BEHOLD-Endometrial02

PI: Pilar Barretina

Endometrio Avanzado

Start Up

GEICO 162-E/ELEVEN

PI: Alejandro Gallego

Endometrio Avanzado

Start Up

ENGOT-en35/GSK 300118

PI: Fernando Gálvez

Endometrio Avanzado

Start Up

ENGOT-en37/Symbiotic-GYN-18

PI: Cristina Martín

Endometrio Avanzado

Start Up

ENGOT-en36/GINECO-EN109b

PI: Pilar Barretina

Endometrio Avanzado

Seguimiento

ENGOT en20/GEICO 124-E/XPORT-EC-042

PI: Alejandro Pérez Fidalgo CoPI: Lorena Fariñas

A PHASE 3, Randomized, placebo-controlled, Double-Blind, multicenter Trial of selinexor in Maintenance therapy After systemic therapy for Patients with P53 Wild-TYPE, Advanced or Recurrent Endometrial carcinoma

Endometrio Avanzado

Seguimiento

ENGOT en 13/GEICO 108-E/DOMENICA

PI: Mª Jesus Rubio CoPI: Pau Guillén

Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting)

Endometrio Avanzado

Seguimiento

ENGOT-EN26/GEICO 150-E/ASCENT-GYN-01

PI: Eva Guerra CoPI: Neus Ferrer Tur

“A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy”

Endometrio Avanzado

Seguimiento

ENGOT-en23/GEICO 132-E/MK 2870

PI: Pilar Barretina

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy

Endometrio Avanzado

Seguimiento

ENGOT-en10/GEICO 92-E/DUO-E

PI: Marta Gil

A Phase 3Trial with Durvalumab-Olaparib in Newly Diagnosed Advanced and Recurrent endometrial cancer

Endometrio Avanzado

Seguimiento

ENGOT-en15/GEICO 111-E/MK-3475-C93

PI: Ignacio Romero

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

Endometrio Avanzado

Seguimiento

ENGOT-en6/GEICO 93-E/RUBY

PI: Ana Oaknin CoPI: Lydia Gaba

A phase 3, randomized, double blind multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus placebo plus Carboplatin-Paclitaxel in patients with recurrent or primary advance endometrial cancer

Otros Quirúrgico

Reclutamiento

Parola

PI: B. Díaz Feijoo

An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL

Otros Quirúrgico

Seguimiento

ENGOT cx4/GEICO 130Q/SENTICOL III

PI: Ignacio Zapardiel

An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL

Cerrado Cáncer de Ovario

ENGOT-ov40/GEICO 71-R/Expression VI

PI: P. Barretina

Caroline meets HANNA – Holistic Analysis of LoNgterm-survival with OvariaNCAncer.

Cerrado Cáncer de Ovario

GEICO 66-O/OLATRA

PI: I. Romero

Phase II studyofOlaparib as maintenanceTherapyafter response totrabectedin-pegylatedliposomaldoxorubicin in recurrentovarian carcinoma.

Cerrado Cáncer de Ovario

ENGOT-ov25/GEICO 48-O/PAOLA-1

PI: Antonio González

Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.

Cerrado Cáncer de Ovario

GEICO 29-O/INOVATION

PI: A. Poveda

Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.

Cerrado Cáncer de Ovario

ENGOT OV27/GEICO 52-O/MORAB

PI: Antonio González

Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.

Cerrado Cáncer de Ovario

ENGOT-ov26/GEICO 54-O/PRIMA

PI: Antonio González

A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.

Cerrado Cáncer de Ovario

GEICO 37-O/NOVA

PI: Y. García

Ensayo clínico fase II de quimioterapia neoadyuvante con o sin Bevacizumab en pacientes con cáncer de ovario.

Cerrado Cáncer de Ovario

GEICO 31-O/NOVA

PI: JM. Del Campo

F III, mantenimiento con niraparib vs placebo en recaída platino sensible.

Cerrado Cáncer de Ovario

ENGOT ov21/GEICO 39-O/SOLO-2

PI: A. Poveda

F III Olaparib vs placebo de mantenimiento tras recaída platino-sensible.

Cerrado Cáncer de Ovario

GEICO 30-Q/DESKTOP III

PI: A. Poveda / S. Martínez

F III cirugía o no en la recaída platino sensible.

Cerrado Cáncer de Ovario

GEICO 33-O/PENELOPE

PI: Antonio González

F III QT +/- pertuzumab en platino-resistente.

Cerrado Cáncer de Ovario

GEICO 42-R/ROSE

PI: Antonio González

Estudio retrospectivo sobre tratamiento del cáncer de ovario.

Cerrado Cáncer de Ovario

GEICO 44-R/RETRO-ROC

PI: I. Romero

Estudio post-autorización observacional restrospectivo y multicéntrico de la combinación con trabectedina y doxorubicinaliposomalpegilada (DLP) en cáncer de ovario recidivante.

Cerrado Cáncer de Ovario

CÓDIGO DE ENSAYO CLÍNICO: GEICO 1302 - ENGOT OV 11 - Array 162-311

PI: I. Romero

The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum

Cerrado Cáncer de Ovario

CÓDIGO DE ENSAYO CLÍNICO: GEICO 1303-ENGOT OV 16- NOVA (ENGOT)

PI: JM. Del Campo

A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

Cerrado Cáncer de Ovario

ENGOT-OV-2b/TRINOVA 3/GEICO-1201

PI: JM. Del Campo

TRINOVA – A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.

Cerrado Cáncer de Ovario

MM-121/GEICO 1202

PI: Antonio González, Andrés Redondo, JM. Rubio, A. Poveda

Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers.

Cerrado Cáncer de Ovario

NCIC-OV 21/GEICO-0902

PI: I. Romero, J. Ponce

Estudio de Fase II-III de quimioterapia intraperitoneal (IP) más intravenosa (IV) frente a carboplatino más Paclitaxel IV en pacientes con carcinoma epitelial de ovario sometidas a cirugía citoreductora óptima posterior a quimioterapia intravenosa neoadyuvante.

Cerrado Cáncer de Ovario

GEICO 1001-CATUMAXOMAB

PI: Ana Oaknin

Ensayo Fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación de pacientes con un carcinoma epitelial de ovario, de trompa de Falopio, o un carcinoma primario peritoneal en segunda o tercera remisión completa clínica.

Cerrado Cáncer de Ovario

AGO-OVAR 12/GEICO 1003

PI: JM. Del Campo

Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con carboplatino y paclitaxel en pacientes con cáncer de ovario avanzado.

Cerrado Cáncer de Ovario

GEICO 1002

PI: Ana Oaknin

Ensayo clínico fase II no controlado, multicéntrico y prospectivo para determinar el beneficio clínico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR -1, -2 , -3, PDGFR-α y β y C-Kit), en pacientes con cáncer de ovario avanzado platino resistentes.

Cerrado Cáncer de Ovario

ICON-6/GEICO 1101

PI: Antonio González

Ensayo clínico multicéntrico del Gynaecologic Cancer Intergroup, controlado doble ciego de Cediranib (AZD 2171), en combinación con quimioterapia basada en platino y como agente único en terapia de mantenimiento, en mujeres con cáncer de ovario que han recaído más de 6 meses tras la finalización de un tratamiento de primera línea basado en platino.

Cerrado Cáncer de Ovario

AURELIA/GEICO 0904

PI: A. Poveda

AURELIA: Ensayo clínico de fase III multicéntrico, abierto, aleatorizado, con dos grupos de tratamiento, de bevacizumab en combinación con quimioterapia frente a quimioterapia sola en pacientes con cáncer epitelial de ovario, carcinoma de trompas de Falopio o peritoneal primario resistente a platino.

Cerrado Cáncer de Ovario

GEICO 0901/AGO-OVAR 16

PI: JM del Campo

Estudio de fase III para evaluar la eficacia y la seguridad de pazopanib en monoterapia frente a placebo entre mujeres con cáncer epitelial de ovario, de trompa de Falopio o peritoneal primario que no hayan progresado después de la quimioterapia de primera línea.

Cerrado Cáncer de Ovario

GEICO 0905-OCTAVIA

PI: Antonio González

A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.

Cerrado Cáncer de Ovario

GEICO 0802/HECTOR-PHASE III-2006

PI: Antonio González, A. Santaballa

Topotecán más carboplatino frente al tratamiento estándar (paclitaxel más carboplatino o gemcitabina más carboplatino) en el tratamiento de pacientes con carcinoma peritoneal, carcinoma de trompas o carcinoma epitelial de ovario plantino-sensibles recidivantes.

Cerrado Cáncer de Ovario

GEICO 0804-R

PI: B. Ojeda

Base de datos de Bevacizumab en recaídas de Cáncer de Ovario.

Cerrado Cáncer de Ovario

GEICO 0801-T

PI: A. Poveda

Estudio retrospectivo de biomarcadores en Cáncer Epitelial de Ovario.

Cerrado Cáncer de Ovario

GEICO 0803-R

PI: Ana Oaknin

Feasibility and toxicity of a modified outpatient regimen of intravenous/ intraperitoneal chemotherapy (IV/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.

Cerrado Cáncer de Ovario

GEICO 0701/ICON-7

PI: A. Cervantes

Estudio aleatorizado del “Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer epitelial de ovario.

Cerrado Cáncer de Ovario

GEICO 0702-T/TOPO IIA

PI: Antonio González

Determinación de la expresión de TOPO IIA en muestras de carcinoma de ovario de pacientes tratadas con doxorubicina liposomal pegilada.

Cerrado Cáncer de Ovario

GEICO 0703/MIMOSA

PI: A. Casado

Ensayo clínico multicéntrico aleatorizado, doble ciego, controlado con placebo, para evaluar el tratamiento de mantenimiento con abagovomab en pacientes afectas de carcinoma epitelial ovárico tras respuesta completa a la quimioterapia de la 1ª línea.

Cerrado Cáncer de Ovario

GEICO 0104

PI: Antonio González

Estudio fase II randomizado del doblete carboplatino-gemcitabina seguido de carboplatino paclitaxel versus carboplatino-paclitaxel en pacientes con recidiva platinosensible de carcinoma de ovario, carcinomatosis peritoneal primaria o carcinoma de trompa.

Cerrado Cáncer de Ovario

GEICO 0101

PI: MA. Izquierdo, A. Cervantes

Ensayo clínico de fase III para evaluar el tratamiento con la combinación cisplatino más topotecán seguido de paclitaxel más carboplatino frente a paclitaxel más carboplatino como tratamiento de primera línea en mujeres con un diagnóstico reciente de cáncer epitelial de ovario avanzado.

Cerrado Cáncer de Ovario

GEICO 0103

PI: B. Ojeda

Estudio fase II, con Gemcitabina en infusión prolongada en pacientes con cáncer epitelial de ovario avanzado resistentes a platino

Cerrado Cáncer de Ovario

GEICO CO22

PI: A. Casado

Validación por GEICO de CAELYX en pacientes con cáncer epitelial de ovario.

Cerrado Cáncer de Ovario

GEICO 0199

PI: Antonio González

Ensayo clínico fase II randomizado (con valoración de calidad de vida) de carboplatino frente a la combinación de taxol y carboplatino en pacientes con recaída de cáncer de ovario platino-sensible.

Cerrado Cáncer de Ovario

GEICO 0299/EORTC 55981/NSGO

PI: MA. Izquierdo, JM del Campo

Ensayo Clínico aleatorizado de Paclitaxel / Epirubicina / Carboplatino en combinación (TEC) vs Paclitaxel / Carboplatino (TC) en el tratamiento de mujeres con cáncer de ovario avanzado.

Cerrado Cáncer de Ovario

ENGOT-ov60/GEICO 98-O/Ramp 201

PI: Ana Oaknin CoPI: Alejandro Pérez Fidalgo

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Cerrado Cáncer de Ovario

ENGOT-ov66/GEICO 104-O/AXLerate-OC

PI: Antonio González CoPI: Pilar Barretina

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Cerrado Cáncer de Ovario

GEICO 55-O/ROLANDO

PI: Alejandro Pérez Fidalgo

Multicentric Single arm Phase II clinical trial, to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients

Cerrado Cáncer de Ovario

ENGOT-ov20/GEICO 30-Q/DESKTOP III

PI: Andrés Poveda

Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer

Cerrado Cáncer de Ovario

ENGOT-ov11/GEICO 40-O/MILO

PI: Ignacio Romero

Randomized Phase III MEK152 vs chemo Low Grade Serous Ovarian Cancer

Cerrado Cáncer de Ovario

ENGOT-ov38/GEICO 62-O/OReO

PI: Andrés Redondo

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)

Cerrado Cáncer de Ovario

ENGOT-ov21/GEICO 39-O/SOLO-2

PI: Andrés Poveda

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

Cerrado Cáncer de Ovario

GEICO 105-O

PI: Mª Jesús Rubio

Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study

Cerrado Cáncer de Ovario

ENGOT-ov25/GEICO 48-O/PAOLA

PI: Antonio González / Raúl Marquez

Cerrado Cáncer de Ovario

ENGOT-ov39/GEICO 63-O/IMAGYN 050

PI: Yolanda García

A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with new diagnosed stage III/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cerrado Cáncer de Ovario

ENGOT-ov26/GEICO 54-O/PRIMA

PI: Antonio González

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Cerrado Cáncer de Ovario

ENGOT-ov29/GEICO 58-O/ATALANTE

PI: Ana Oaknin

A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.

Cerrado Cáncer de Ovario

ENGOT-ov34/GEICO 65-O/AGO-OVAR 2.29

PI: Andrés Redondo CoPI: Pilar Barretina

Atezolizumab in combination with Bevacizumab +/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer – a randomised trial

Cerrado Cáncer de Ovario

ENGOT-ov41/GEICO 69-O/ANITA

PI: Antonio González

A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months

Cerrado Cáncer de Ovario

ENGOT-ov46/GEICO 76-O/DUO-O

PI: Mª. Jesús Rubio

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients

Cerrado Cáncer de Ovario

ENGOT-ov44/GEICO 77-O/FIRST

PI: Andrés Redondo CoPI: Lydia Gaba

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

Cerrado Cáncer de Cérvix

ENGOT-Cx6/GEICO 73-C

PI: Antonio González

A Phase 2 Trial of TisotumabVedotin (HuMax®-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.

Cerrado Cáncer de Cérvix

ENGOT-CX1/GEICO 43-O

PI: MJ Rubio

Estudio de fase II, de tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg/m2de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante.

Cerrado Cáncer de Cérvix

GEICO 61-C/AIM2CERV

PI: Ana Oaknin

Phase 3 of ADX11-001 administered following chemoradiation as adjuvant treatment for HRLACC.

Cerrado Cáncer de Cérvix

GEICO 46-O/CECILIA

PI: Andrés Redondo

Fase II carbo-paclitaxel-bevacizumab en primera línea del carcinoma de cérvix persistente, recurrente o diseminado.

Cerrado Cáncer de Cérvix

GOG-0240/GEICO-0903

PI: Ana Oaknin

Ensayo en Fase III aleatorizado de Cisplatino más Paclitaxel con y sin Bevacizumab frente al doblete sin platino, Topotecan más Paclitaxel, con y sin Bevacizumab, en carcinoma de cérvix en estadio IVB, recurrente o persistente.

Cerrado Cáncer de Cérvix

GEICO 2005/01

PI: MJ Rubio

Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de cáncer de cérvix persistente o recidivante tras fracaso de tratamiento de primera línea con derivados del platino.

Cerrado Cáncer de Cérvix

ENGOT-cx9/GEICO 72-C/EMPOWER Cx-1 // REGENERON

PI: Ana Oaknin

Randomized, open-label, phase III clinical trial of REGN2810 compared to investigator's choice chemotherapy treatment for recurrent or metastatic platinum-resistant cervical carcinoma

Cerrado Cáncer de Cérvix

ENGOT-cx1/GEICO 43-C

PI: Mª. Jesús Rubio

Cerrado Cáncer de Cérvix

ENGOT-cx10/GEICO 68-C/BEATcc

PI: Ana Oaknin

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Cerrado Cáncer de Endometrio

ENGOT-EN3/GEICO 64-E/PALEO

PI: C. Mendiola

A phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.

Cerrado Cáncer de Endometrio

GEICO 59-RT/Retro LMS

PI: MJ Rubio

Yondelis en leiomiosarcoma uterino: estudio retrospectivo + biomarcadores.

Cerrado Cáncer de Endometrio

GEICO P02868/GEIS 7

PI: Andrés Poveda

Ensayo Fase IV-II de Temozolamida en esquema de administración oral continua en el tratamiento de los Sarcomas Ginecológicos.

Cerrado Cáncer de Endometrio

ENGOT-en5/GEICO 67-E/SIENDO

PI: Alejandro Pérez Fidalgo

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA

Cerrado Cáncer de Endometrio

GEICO 70-E/WI 231461 AVE-IIG-03

PI: Jose Mª Piulats

A PHASE II MULTICENTER, OPEN-LABEL, SINGLE ARM TRIAL OF AVELUMAB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT/METASTATIC ENDOMETRIAL CANCER

Cerrado Cáncer de Endometrio

ENGOT-en7/GEICO 75-E/ATTEND

PI: Pilar Barretina

Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Cerrado Cáncer de Endometrio

ENGOT-en9/GEICO 83-E/LEAP-001

PI: Mª Jesús Rubio

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma

Cerrado Cáncer de Endometrio

ENGOT-en11/GEICO 94-E/MK‐3475‐B21

PI: Pilar Barretina CoPI: Lorena Fariñas

A Phase 3, Randomized, Double‐Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High‐Risk Endometrial Cancer After Surgery With Curative Intent

Cancelado Cáncer de Ovario

ENGOT-ov73/GEICO 123-O/LUPPA-1

PI: Antonio González CoPI: Luis Manso

A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin in Combination with Paclitaxel vs. Platinum-based Chemotherapy or Weekly Paclitaxel as Treatment in Patients with Relapsed Platinum-sensitive Ovarian Cancer

Cancelado Cáncer de Ovario

ENGOT-ov71/GEICO 121-O/UP-NEXT

PI: Antonio González CoPI: Marga Romero

Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive, High-grade Serous Ovarian Cancer

Cancelado Cáncer de Ovario

ENGOT OV75/ GEICO 128-O/INNOVATE 5

PI: Margarita Romero Martín CoPI: Gloria Marquina

A Pivotal, Randomized Controlled, Open-Label Study of Tumor Treating Fields (TT Fields) in Patients with Recurrent Ovarian Cancer in Whom Platinum Is an Option

Cancelado Cáncer de Ovario

ENGOT gyn2/GEICO 97-O/BOUQUET

PI: Andrés Redondo

A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.

Cancelado Cáncer de Ovario

ENGOT ov79/GEICO 134-O/STRO-002-GM3 (REFRaME-01)

PI: Ana Oaknin

A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)